Facebook
Twitter
LinkedIn
ForwardDEA MATE ACT FOR PRESCRIBERS AND OPIOID TRAINING
Substance Use Disorders and Addiction Education DEA Requirements
This training was developed to meet the one-time, eight-hour training requirement issued by the Drug Enforcement Administration (DEA) of the MATE Act, which officially went into effect back in June of 2023. It is designed for all registered practitioners for treating and managing patients with opioid or other substance use disorders. Physicians are required to complete this training whether they have been practicing for a long time, or if they are brand-new into practice. The credit value for each training is based upon the length of time to complete the online course.
The CME activities listed within this bundle can be taken in any order to fulfill the MATE Act requirements. The full requirement is eight hours of learning; however, it can be broken up, therefore, training for the MATE Act can be done across multiple sessions. In addition, physicians can count previous training they have completed that was directed towards treating and managing patients with opioid or other substance use disorders towards these eight hours as well.
Target Audience
Effective June 27, 2023, the federal legislation (PDF) states that health practitioners who apply for or renew their Drug Enforcement Administration (DEA) registration to prescribe controlled substances must attest they have completed the training by checking a box on their online DEA application form. The deadline for satisfying this new training requirement is the date of a practitioner's initial application for DEA registration or their next scheduled DEA registration renewal. DEA registration is valid for a three-year period before it must be renewed. If training was already completed any time prior to June 27, 2023, there is no need to complete another eight hours of training to satisfy the MATE Act.
Health practitioners are considered to have satisfied this requirement if they are:
- Board certified in addiction medicine or addiction psychiatry by the American Board of Medical Specialties, the American Board of Addiction Medicine or the American Osteopathic Association.
- A graduate in good standing from a U.S. medical, dental, physician assistant or advanced practice nursing school within five years of their application for DEA registration, who successfully completed eight hours of training on:
- Treating and managing patients with opioid and other substance use disorders, including the appropriate clinical use of all drugs approved by the Food and Drug Administration for the treatment of a substance use disorder
- Safe pharmacological management of dental pain and screening, brief intervention, and referral for appropriate treatment of patients with or at risk of developing opioid and other substance use disorders
- Have engaged in a total of eight hours of training on treatment and management of patients with opioid or other substance use disorders from any accredited organization who provides the training.
Planning Committee Acknowledgement: The following individuals helped plan and organize this collection of presenters and topics.
Bernard J. Costello MD, DMD
Associate Vice Chancellor for Health Sciences Integration
Professor and Chief, Pediatric Oral and Maxillofacial Surgery
Dr. Costello serves as the Associate Vice Chancellor for Health Science Integration and works with the senior administration in the Health Sciences and UPMC. He has been a full-time faculty member at Pitt since 2001 and is the former dean of the School of Dental Medicine. Dr. Costello is Professor of Oral and Maxillofacial Surgery, and Chief of Pediatric Maxillofacial Surgery at UPMC Children’s Hospital where he the longest serving surgeon on the cleft-craniofacial team. Dr. Costello earned his doctorates in dentistry and medicine from the University of Pennsylvania. Following his residency training at the University of Pennsylvania and Children’s Hospital of Philadelphia, Dr. Costello completed a pediatric craniofacial fellowship at the Posnick Center for Facial Surgery and Georgetown University Medical Center. Dean of the University of Pittsburgh School of Dental Medicine.
The increased use of opioid pain relievers, including those routinely prescribed for dental procedures, has contributed to the opioid epidemic and drug overdose deaths. To help reverse this trend, Dr. Costello authored The Costello Pain Care PledgeTM, a commitment to responsible pain management by health care providers to demonstrate their commitment to responsibly and consciously avoid the preferential use of addictive medications whenever possible, based upon the most current wisdom and principles. The Pledge was developed to reinforce physician accountability in prescribing pain medications to demonstrate their devotion to these same principles in their own patients’ care.
Dr. Costello also created The Costello Guidelines for Prescribing Pain Medications, which are based on evidence that alternative medications generally work as well or even better than opioids for managing pain after dental work, without the side effects of nausea, vomiting, constipation and potential for misuse. Among other factors, the guidelines take into account the severity, duration and individual risk considerations when prescribing pain medications for a particular person following various dental procedures.
The Costello Guidelines for Prescribing Pain Medications and the Costello Pain Care Pledge represent an important change in the way health care providers anywhere can prudently manage pain following a procedure, or as part of ongoing treatment.
Payel Jhoom Roy, MD, MSc
Clinical Director of the Addiction Medicine Consult Service, UPMC Presbyterian
Assistant Professor of Medicine, University of Pittsburgh School of Medicine
Dr. Roy is an Assistant Professor of Medicine at the University of Pittsburgh School of Medicine. She works as a health services researcher in addiction treatment and is a board-certified Internal Medicine and Addiction Medicine physician. Her clinical expertise is in providing low-barrier access to treatment for opioid use disorder for general medical patients, both in the hospital and in the outpatient setting. As the Director of the Addiction Medicine Consult Service at University of Pittsburgh Medical Center, Dr. Roy is a local leader for developing policies, strategies, and communication skills that ensure patients receive evidence-based treatment for substance use disorders. She is an NIH-funded clinician-investigator and fellowship-trained clinician-educator. As a clinician-educator, Dr. Roy has mentored trainees in educational projects around addiction treatment and taught in courses at the Boston University School of Medicine and the University of Pittsburgh School of Medicine. She has also precepted residents and fellows in general medicine and in the care of patients with substance use disorders. Dr. Roy is currently multiple principal investigator (MPI) on NIH-funded research using mixed methods to study the association between medications for opioid use disorder and dental health. As a physician-researcher, Dr. Roy has published in peer-reviewed journals, notably in low-barrier access to treatment. Dr. Roy has published both original research and opinion pieces in high-impact journals, including JAMA. Her goal is to ensure all providers feel comfortable managing patients with substance use disorders, regardless of specialty.